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A B S T R A C T
This study assessed the persistence of humoral
(neutralising antibody titre to vaccinia virus) and
cellular (immediate vaccinia-specific interferon
(IFN)-c-producing T-cell) immunities to smallpox
in a Korean population. Individuals who were
vaccinated 25–60 years previously had higher
neutralising antibody titres (geometric mean titre
(GMT) 13.7; 95% CI 11.0–17.2) than vaccinia-
naive individuals (GMT 6.7; 95% CI 5.5–8.0;
p <0.001). However, there was no significant
difference in cellular immunity between indivi-
duals vaccinated previously and vaccinia-naive
individuals, and only 15% of the individuals
vaccinated previously displayed an immediate
IFN-c-producing effector-memory response in
ELISPOT assays.
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This study assessed the persistence of humoral
(neutralising antibody titre to vaccinia virus) and
cellular (immediate vaccinia-specific interferon
(IFN)-c-producing T-cell) immunities to smallpox
among healthy Korean adults.
Sera and peripheral blood mononuclear cells
(PBMCs) were obtained from healthy volunteers,
aged 20–60 years, between January 2003 and
December 2004. PBMCs were isolated within 6 h
of sample collection, using Ficoll-Hypaque den-
sity gradients, and were cryopreserved. Neutral-
isation antibody assays were performed as
described previously [1–3]. Cell-mediated im-
mune responses to smallpox vaccination were
assessed as immediate vaccinia-specific IFN-c-
producing T-cell response by ELISPOT assays.
The detailed protocol has been described previ-
ously [3]. Spots were scored as positive if there
were ‡20 vaccinia-specific spot-forming cells
(SFCs) ⁄million PBMCs (after subtracting the back-
ground obtained with unstimulated cells). This
threshold for positivity was established after
taking into account the variability of the back-
ground obtained with cells alone (mean ± stand-
ard deviation (SD), 9.5 ± 11.1 SFCs ⁄ 106 PBMCs;
range 0–58) and the SFC range among 16 vaccinia-
naive individuals used as negative controls
(median 1.2 SFCs ⁄ 106 PBMCs; range 0–
19 SFCs ⁄ 106 PBMCs).
Eighty-three volunteers participated in the
study. The mean age (±SD) of the subjects was
33.1 years (±7.3 years), and 66 (80%) were male.
Of the 83 participating individuals, 63 (76%) had
a history of smallpox vaccination or a scar from
vaccinia vaccination, and 20 (24%) were vaccinia-
naive. Neutralising antibody titres were signifi-
cantly higher among the individuals vaccinated
previously (geometric mean titre (GMT) 13.7;
95% CI 11.0–17.2) than among the vaccinia-naive
individuals (GMT 6.7; 95% CI 5.5–8.0; p <0.001).
PBMCs were obtained successfully from 55
(66%) subjects, of whom 39 (71%) had been
vaccinated previously and 16 (29%) were vacci-
nia-naive. Only 15% (6 ⁄ 39) of the previously
vaccinated subjects in this population displayed
an immediate IFN-c-producing effector-memory
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response in ELISPOT assays. There was no signi-
ficant difference in cellular immunity between
individuals vaccinated previously and vaccinia-
naive individuals (positive immediate IFN-c-pro-
ducing effector-memory responses were 15%
(6 ⁄ 39) in individuals vaccinated previously vs.
0% (0 ⁄ 16) in vaccinia-naive individuals; p 0.17).
Neutralising antibody titres and vaccinia-specific
IFN-c-producing effector-memory responses,
grouped according to the length of time since
smallpox vaccination, are shown in Fig. 1.
There have been several reports concerning
the persistence of humoral immunity following
smallpox vaccination. El-Ad et al. [4] showed that
neutralising titres for vaccinated individuals in
Israel remained stable for at least 30 years (GMT
10.5; 95% CI 6.8–16.4). More recently, Hammarl-
und et al. [1] and Hatakeyama et al. [5] reported
that vaccinia-specific antibody, assayed by
enzyme immunoassay, remained stable for 1–
75 years following smallpox vaccination. Crotty
et al. [6] also demonstrated that vaccinia-specific
neutralising antibody levels are low and stable in
vaccinated individuals for at least 30 years fol-
lowing smallpox vaccination. Thus, the present
finding that neutralising antibody titres were
maintained for 25–50 years following smallpox
vaccination is consistent with these earlier studies.
There are few data, and some controversy,
concerning the persistence of cell-mediated
immunity following smallpox vaccination. Recent
in-vitro studies revealed that >90% of individuals
vaccinated previously retained substantial cellu-
lar immunity, even 25–75 years following small-
pox vaccination [1,6]. In contrast, Combadiere
et al. [7] reported that only 20% of volunteers
vaccinated 13–25 years previously displayed IFN-
c-producing effector-memory responses. Hsieh
et al. [8] found that T-cell responses against
vaccinia virus started to decline within 20–
30 years following smallpox vaccination, and
were then as low as those in unvaccinated
subjects [8]. The present study found that only
15% of individuals vaccinated previously dis-
played an immediate IFN-c-producing effector-
memory response. One explanation could be that
the assays for cell-mediated immunity are not
standardised. Alternatively, the ELISPOT assay
may have been neither sensitive nor specific
enough to detect the presence of latent memory
vaccinia virus-specific CD8+ T-cells before revac-
cination [3]. A proliferation assay (proliferative or
central memory T-cells) or intracellular IFN-c
staining might be more appropriate than an
ELISPOT assay (immediate effector-memory T-
cells) for detecting these extremely low frequen-
cies of vaccinia-specific T-cells [7].
Although there is controversy concerning the
role of humoral immunity in protection against
smallpox or vaccinia virus infections [9], there is
evidence suggesting that an effective humoral
immune response may have a role in protecting
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Fig. 1. (a) Neutralising antibody titres and (b) vaccinia-specific interferon (IFN)-c-producing effector-memory responses,
grouped according to the length of time since smallpox vaccination. The geometric mean titre (a) or mean (b) is represented
by the horizontal lines. Line brackets indicate differences between two groups (Mann–Whitney U-test). Neutralising
antibody titres or vaccinia-specific IFN-c-producing effector-memory responses between periods since smallpox
vaccination had p values of 0.01 and 0.85, respectively (Kruskal–Wallis analysis of variance) for the entire distribution.
SFC, spot-forming cells; PBMC, peripheral blood mononuclear cells.
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individuals from variola or vaccinia virus attack
by blocking viral attachment to the host cells.
Previous small-scale studies have demonstrated
that smallpox contacts who have neutralising
titres above a certain level are subsequently
protected against smallpox [10,11]. Furthermore,
several studies have demonstrated the use of
vaccinia immune globulin to prevent smallpox in
individuals exposed to patients with smallpox
[12,13]. However, it is not known precisely which
components of neutralising antibody to vaccinia
virus contribute to protective immunity against
smallpox. Law et al. [14] showed that anti-extra-
cellular enveloped virus neutralising antibody
was more important in protecting against the
lethal challenge of vaccinia virus in a mouse
pneumonia model than was anti-intracellular
mature virus neutralising antibody. Viner and
Isaacs [15] demonstrated that anti-extracellular
enveloped virus antibody showed a significantly
greater decrease several decades after smallpox
vaccination than did anti-intracellular mature
virus antibody. In addition, there is controversy
as to which specific antibodies for viral protein
targets are important for protective immunity
against smallpox [16], and it remains to be
determined whether non-neutralising antibody
to vaccinia virus also contributes to protection
against smallpox. Further studies are required to
elucidate these issues.
It can be inferred from the present study that, in
the event of an unexpected smallpox attack, the
younger (vaccinia-naive) age group, with no
residual immunity, might experience a more
severe course of smallpox disease than older
(vaccinated previously) individuals with residual
immunity, as also shown by the previous epide-
miological data [17]. However, this low level of
residual immunity to smallpox, decades after
smallpox vaccination, could not prevent smallpox
disease, and individuals with this residual immu-
nity would have sub-clinical or mild smallpox
disease [18]. Thus, the data from this study
support previous epidemiological observations
that smallpox vaccination probably provides
long-term protection against a fatal outcome
[17,19].
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